Overview
Français
ABSTRACT
Photodynamic therapy, also called PDT has been continuously developed over the last thirty years, and has become a major alternative approach in the treatment of a large number of cancers. At the origin of this development, progress in the comprehension of physico-chemical processes involved in the PDT, and the identification of parameters allowing for the improvement of its efficiency have led to a spectacular optimization of the structure of the photosensitizers involved. These evolutions are presented along with the latest strategies implemented within this framework.
Read this article from a comprehensive knowledge base, updated and supplemented with articles reviewed by scientific committees.
Read the articleAUTHORS
-
Cyrille MONNEREAU: Doctorate in chemical sciences from the University of Nantes - Senior lecturer with CNRS Chair at the École normale supérieure de Lyon - Researcher at the ENS Lyon Chemistry Laboratory (Lyon 1 University, UCBL), UMR5182 "Chemistry for Optics" team.
-
Chantal ANDRAUD: Doctorate in chemical sciences from the University of Paris VI - CNRS Research Director - Director, ENS Lyon Chemistry Laboratory (University Lyon 1, UCBL), UMR5182 - Head of the "Chemistry for Optics" team
INTRODUCTION
Field: Non-invasive cancer therapy techniques
Degree of technology diffusion: Emergence | Growth | Maturity
Technologies involved: chemical synthesis, diode and laser technologies, (bio)photonics
Areas of application: non-surgical therapy of cancer and diseases associated with cellular aging
Main French players :
Competitive clusters :
Competence centers: 60 hospitals equipped in France (leader: CHU d'Angers – urology department); "Conception Synthèse et vectorisation de biomolécules" unit (CNRS UMR 176, Institut Curie, Paris, France); ENSL chemistry laboratory (UMR 5182, ENSL, University of Lyon, France).
Other players worldwide :
Hospital research centers: PhotoDynamic Therapy Center (Roswell Park Cancer Institute, Buffalo); PhotoDynamic Therapy Center-LW Jenkins Cancer Center (Pitt County Memorial Hospital-BrodyScool of Medicine, East Carolina University); Moscow PA Gertsen Oncology Research Institute; Department of Cancer Research and Molecular Medicine (Norwegian University of Science and Technology, NTNU, Trondheim)
Photosensitizers: Draxis Pharma, Axcan Pharma, Novartis, Biolitec Pharma, DUSA, Galderma
Light sources: Coherent Inc, Biolitec, Photocure, PhotoMedex
Contact : [email protected] , [email protected]
The Ultimate Scientific and Technical Reference
This article is included in
Healthcare technologies
This offer includes:
Knowledge Base
Updated and enriched with articles validated by our scientific committees
Services
A set of exclusive tools to complement the resources
Practical Path
Operational and didactic, to guarantee the acquisition of transversal skills
Doc & Quiz
Interactive articles with quizzes, for constructive reading
Photodynamic therapy: chemical evolution of photosensitizers
Photodynamic therapy (PDT): background and principles
Bibliography
Websites
Haute Autorité de Santé website, information on :
Visudyn® http://www.has-sante.fr/portail/jcms/c_486276/visudyne
Foscan™ http://www.has-sante.fr/portail/jcms/c_1012344/foscan?xtmc==2
...Events
Exhibition: OPTO, Paris, Porte de Versailles, for players in the optics and photonics industry http://www.mesurexpovision.com/les-salons/opto/opto
Standards and norms
- Medical devices – Quality management systems – Requirements for regulatory purposes - ISO 13485 - 2003
Patents
"Preparation of hematoporphyrin dimers and trimers for photodynamic therapy" WO 9000392 A1 19900125
"Preparation of dihydro and tetrahydro derivatives of porphyrins for cancer phototherapy EP337601 A1 19891018
"Radiation-absorbing dyes for treating illnesses assocd. with abnormal vasculature" WO 2001039764 A2 20010607
Directory
Manufacturers – Suppliers – Distributors (non-exhaustive list)
Photosensitizers
Novartis Pharma http://www.novartis.com
DraxisPharma http://www.photofrin.com/
The Ultimate Scientific and Technical Reference
